Pierre-louis L. Carron
Grenoble, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal: Annals of the rheumatic diseases
Published: June 24, 2023
Characteristics of ANCA-associated vasculitis with aneurysms: Case series and review of the literature.
Journal: Autoimmunity reviews
Published: January 23, 2023
Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Journal: JAMA network open
Published: July 08, 2022
Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study.
Journal: Journal of internal medicine
Published: November 10, 2021
Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract.
Journal: Seminars in arthritis and rheumatism
Published: November 26, 2020
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Journal: Annals of internal medicine
Published: June 02, 2020
Corrigendum to "Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation" [Thromb. Res. 166 (2018) 113-121].
Journal: Thrombosis research
Published: June 12, 2018
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Journal: Annals of the rheumatic diseases
Published: November 29, 2017
Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation.
Journal: Thrombosis research
Published: November 25, 2017
Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models.
Journal: Blood purification
Published: November 07, 2017
Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease.
Journal: BMC nephrology
Published: September 23, 2017
Last Updated: 09/26/2026